SI2032531T1 - Soli N-hidroksi-3-(4-(((2-(2-metil-1H-indol-3-il)etil)amino)metil)fenil)-2E-2 -propenamida - Google Patents

Soli N-hidroksi-3-(4-(((2-(2-metil-1H-indol-3-il)etil)amino)metil)fenil)-2E-2 -propenamida

Info

Publication number
SI2032531T1
SI2032531T1 SI200731762A SI200731762A SI2032531T1 SI 2032531 T1 SI2032531 T1 SI 2032531T1 SI 200731762 A SI200731762 A SI 200731762A SI 200731762 A SI200731762 A SI 200731762A SI 2032531 T1 SI2032531 T1 SI 2032531T1
Authority
SI
Slovenia
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
SI200731762A
Other languages
English (en)
Inventor
Murat Acemoglu
Joginder S. Bajwa
Piotr Karpinski
Dimitris Papoutsakis
Joel Slade
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2032531(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2032531T1 publication Critical patent/SI2032531T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200731762A 2006-06-12 2007-06-07 Soli N-hidroksi-3-(4-(((2-(2-metil-1H-indol-3-il)etil)amino)metil)fenil)-2E-2 -propenamida SI2032531T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14
PCT/US2007/070558 WO2007146715A1 (en) 2006-06-12 2007-06-07 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
EP07784348.0A EP2032531B1 (en) 2006-06-12 2007-06-07 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Publications (1)

Publication Number Publication Date
SI2032531T1 true SI2032531T1 (sl) 2016-05-31

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731762A SI2032531T1 (sl) 2006-06-12 2007-06-07 Soli N-hidroksi-3-(4-(((2-(2-metil-1H-indol-3-il)etil)amino)metil)fenil)-2E-2 -propenamida

Country Status (38)

Country Link
US (3) US20090197936A1 (sl)
EP (1) EP2032531B1 (sl)
JP (2) JP2009540005A (sl)
KR (2) KR101629352B1 (sl)
AR (1) AR061298A1 (sl)
AU (1) AU2007257962B2 (sl)
BR (1) BRPI0712771A2 (sl)
CA (1) CA2654439C (sl)
CL (1) CL2007001692A1 (sl)
CR (1) CR10439A (sl)
DK (1) DK2032531T3 (sl)
EA (1) EA015212B1 (sl)
EC (1) ECSP088979A (sl)
ES (1) ES2570934T3 (sl)
GE (1) GEP20105125B (sl)
GT (1) GT200800279A (sl)
HK (1) HK1126496A1 (sl)
HN (1) HN2008001859A (sl)
HR (1) HRP20160291T1 (sl)
HU (1) HUE027126T2 (sl)
IL (1) IL195087A (sl)
JO (1) JO3138B1 (sl)
MA (1) MA30563B1 (sl)
ME (1) ME00531B (sl)
MX (1) MX2008015901A (sl)
MY (1) MY147345A (sl)
NO (1) NO341871B1 (sl)
NZ (1) NZ572547A (sl)
PE (1) PE20080937A1 (sl)
PL (1) PL2032531T3 (sl)
RS (1) RS54640B1 (sl)
SI (1) SI2032531T1 (sl)
SM (1) SMP200900002B (sl)
SV (1) SV2008003126A (sl)
TN (1) TNSN08501A1 (sl)
TW (1) TWI409254B (sl)
UY (1) UY30403A1 (sl)
WO (1) WO2007146715A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149337A (en) 2006-06-12 2013-08-30 Novartis Ag Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
MY149337A (en) * 2006-06-12 2013-08-30 Novartis Ag Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
MA30563B1 (fr) 2009-07-01
CA2654439C (en) 2014-08-05
TNSN08501A1 (en) 2010-04-14
US20090197936A1 (en) 2009-08-06
TW200815343A (en) 2008-04-01
CR10439A (es) 2009-01-15
AU2007257962A1 (en) 2007-12-21
RS54640B1 (en) 2016-08-31
GT200800279A (es) 2010-06-16
KR20150029765A (ko) 2015-03-18
SMAP200900002A (it) 2009-01-14
GEP20105125B (en) 2010-11-25
JP2009540005A (ja) 2009-11-19
EP2032531A1 (en) 2009-03-11
NO341871B1 (no) 2018-02-12
US20100286409A1 (en) 2010-11-11
DK2032531T3 (en) 2016-04-11
IL195087A (en) 2012-10-31
US20110112308A1 (en) 2011-05-12
KR20090026281A (ko) 2009-03-12
CL2007001692A1 (es) 2008-05-09
JO3138B1 (ar) 2017-09-20
HK1126496A1 (zh) 2009-09-04
MY147345A (en) 2012-11-30
PL2032531T3 (pl) 2016-07-29
JP2013256542A (ja) 2013-12-26
JP5771257B2 (ja) 2015-08-26
ES2570934T3 (es) 2016-05-23
SMP200900002B (it) 2010-01-19
AU2007257962B2 (en) 2011-06-23
ECSP088979A (es) 2009-01-30
EA015212B1 (ru) 2011-06-30
TWI409254B (zh) 2013-09-21
UY30403A1 (es) 2008-01-31
SV2008003126A (es) 2011-07-05
EA200802382A1 (ru) 2009-06-30
PE20080937A1 (es) 2008-08-29
NZ572547A (en) 2011-06-30
BRPI0712771A2 (pt) 2012-09-25
HN2008001859A (es) 2011-07-19
KR101629352B1 (ko) 2016-06-13
NO20090128L (no) 2009-03-11
HUE027126T2 (en) 2016-08-29
EP2032531B1 (en) 2016-02-10
MX2008015901A (es) 2009-01-12
WO2007146715A1 (en) 2007-12-21
CA2654439A1 (en) 2007-12-21
AR061298A1 (es) 2008-08-20
IL195087A0 (en) 2009-08-03
ME00531B (me) 2011-10-10
HRP20160291T1 (hr) 2016-04-22

Similar Documents

Publication Publication Date Title
SI2032531T1 (sl) Soli N-hidroksi-3-(4-(((2-(2-metil-1H-indol-3-il)etil)amino)metil)fenil)-2E-2 -propenamida
IL195015A0 (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
HK1126495A1 (en) Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3- yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide n--3-[4-[[[2-(2--1h--3-)]]]]-2e-2-
ZA200809383B (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
IL233836A0 (en) Method for preparing n-hydroxy-3-[4-[[[2-(2-methyl-h1-indol-3-yl)ethyl]amino]methyl]phenyl]-e2-2-propanamide
ZA200809094B (en) Polymorphs of N-hydroxy-3-[4[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]pheny]-2E-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida